2. 疾患モデリングル製品 Cell Cycle/DNA Damage Apoptosis Autophagy Immunology/Inflammation Metabolic Enzyme/Protease
  3. Urinary System Disease Models DNA Alkylator/Crosslinker Ferroptosis Autophagy Pyroptosis Lipoxygenase
  4. Cisplatin

シスプラチン  (Synonyms: CDDP; Cisplatin; Cis-Platinum)

製品番号: HY-17394 純度: 99.30%
COA 取扱説明書 Technical Support

Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 15663-27-1

容量 価格（税別） 在庫状況 数量
5 mg $25 在庫あり
10 mg $35 在庫あり
50 mg $45 在庫あり
100 mg $60 在庫あり
500 mg $150 在庫あり
1 g $228 在庫あり
5 g   お問い合わせ  
10 g   お問い合わせ  

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 769 publication(s) in Google Scholar

シスプラチン 関連抗体

Top Publications Citing Use of Products

顧客検証

IHC
WB
In Vivo Efficacy Study
IF
RT-PCR
Cell Proliferation/Viability Assay

    Cisplatin purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Jun 20;11(25):eadt3075.  [Abstract]

    Brain slices of mice were stained with hematoxylin andeosin (H&E) at the endpoint. BCBM model mice, either cisplatin (4 mg/kg, intraperitoneally) or ʟ-ASNase (L-Asparaginase; 0.2 mg per mouse, intraperitoneally) was administered weekly or every 2 days for 2 weeks, respectively.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Sci Adv. 2025 Jun 20;11(25):eadt3075.  [Abstract]

    BLI was conducted at regular intervals. Representative BLI images and line chart of radiance. BCBM model, Mice were administered cisplatin (4 mg/kg, intraperitoneally) weekly or ʟ-ASNase (0.2 mg per mouse, intraperitoneally) every 2 days.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2024 Oct 31;23(1):243.  [Abstract]

    Cisplatin (2 μg/mL; 24-72 h) combined with Venetoclax (10-160 μM; 12-72 h) and Hydroxychloroquine (12.5-50 μM; 12-72 h) significantly inhibits the growth of H446/cDDP cells.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Mar:73:101059.

    Proliferation capacity of cells assessed using colony formation experiments after treatment with 10 μM cisplatin in combination with 10 μM 2-DG or 5 μM oxamate or 15 μM Nala.
    2-DG and oxamate synergize with cisplatin could inhibit BCa cell proliferation and colony-forming ability.

    Cisplatin purchased from MedChemExpress. Usage Cited in: ACS Nano. 2024 Nov 12;18(45):31401-31420.  [Abstract]

    Cisplatin (5-30 μM; 24 h) exhibits an IC50 value of 14.56 μM for inhibiting the viability of A549 cells.

    Cisplatin purchased from MedChemExpress. Usage Cited in: ACS Nano. 2024 Nov 12;18(45):31401-31420.  [Abstract]

    Cisplatin (5-30 μM; 24 h) demonstrates an IC50 value of 7.41 μM for inhibiting the viability of H1299 cells.

    Cisplatin purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2024 Mar 7;134(10):e172716.  [Abstract]

    The given cell lines were treated with 250 nM osimertinib (Osim), 1.25 μM Etoposide (VP-16), 125 nM Doxorubicin (DXR), 5 nM Paclitaxel, 10 μM Cisplatin, 25 μM Carboplatin, 25 nM Gemcitabine, 20 nM 5-Fluorouracil (5-FU), 25 μM Cyclophosphamide, 25 μM Capecitabine, or 10 nM Vincristine alone or in combination for 3 days. Cell numbers were then measured using the SRB assay.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 Dec;33(12):904-922.  [Abstract]

    Normal FHs 74 cell lines were pretreated with Mannose (20 mM) for 2 h, and then Cisplatin (10 μg/mL) for 24 h to assess pyroptotic features (including characteristic morphology, GSDME cleavage, and LDH release), and the cleaved caspase-3 and its substrate PARP levels were also detected.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 Dec;33(12):904-922.  [Abstract]

    Normal FHs 74 cell lines were pretreated with Mannose (20 mM) and DON (40 μM) for 2 h, and then Cisplatin (10 μg/mL) for 24 h to assess pyroptotic features (including characteristic morphology, GSDME cleavage, and LDH release), and the cleaved caspase-3 and its substrate PARP levels were also detected.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 Dec;33(12):904-922.  [Abstract]

    Normal NRK-52E cell lines were pretreated with Mannose (20 mM) for 2 h, and then Cisplatin (10 μg/mL) for 24 h to assess pyroptotic features (including characteristic morphology, GSDME cleavage, and LDH release), and the cleaved caspase-3 and its substrate PARP levels were also detected.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Res. 2023 Dec;33(12):904-922.  [Abstract]

    Normal NRK-52E cell lines were pretreated with Mannose (20 mM) and DON (40 μM) for 2 h, and then Cisplatin (10 μg/mL) for 24 h to assess pyroptotic features (including characteristic morphology, GSDME cleavage, and LDH release), and the cleaved caspase-3 and its substrate PARP levels were also detected.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2197836.  [Abstract]

    Cisplatin (CDDP; 3.33 μM or 1.67 μM; 96 h) increases the protein expression of p53 and p21 in ECA-109 and KYSE-150 cells (3.33 μM 1 μg/ml in ECA-109 cells, 1.67 μM 0.5 μg/ml in KYSE-150 cells).

    Cisplatin purchased from MedChemExpress. Usage Cited in: Gut Microbes. 2023 Jan-Dec;15(1):2197836.  [Abstract]

    Cisplatin (CDDP; 3.33 μM or 1.67 μM; 96 h) suppresses the proliferation of ECA-109 and KYSE-150 cells (3.33 μM 1 μg/ml in ECA-109 cells, 1.67 μM 0.5 μg/ml in KYSE-150 cells).

    Cisplatin purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2023 Aug 20:669:61-67.

    Cisplatin (25, 50 μM; 24 h) significantly increases the expression of caspase-3 in PK-15 cells.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Mol Cancer. 2021 Apr 4;20(1):62.  [Abstract]

    LL2 cells were treated by cisplatin (2.5 μM and 5 μM) for 24 h and collected. The relative mRNA expression of CXCL1, CXCL2, CXCL3 and MIF of LL2 cells following cisplatin treatment.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761.  [Abstract]

    IB analysis of the level of cleaved-caspase 3 and cleaved-PARP1 in the indicated chemotherapy-treated xenograft tumors. GAPDH served as the loading control.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Nat Commun. 2019 Aug 21;10(1):3761.  [Abstract]

    Genotoxic stress-induced β-catenin signaling is activated via a TCF- or FOXO-independent mechanism. Representative images of the subcellular localization of β-catenin in the indicated cells treated with CPT (10 μM, 1 h), IR (10 Gy), and CDDP (10 μM, 1 h), as analyzed by immunofluorescence staining.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cancer Res. 2018 Oct 1;78(19):5694-5705.  [Abstract]

    WT and S47 E1A/RAS cells are treated with 10μM CDDP for 24 hours in the presence or absence of the protein synthesis inhibitor Cycloheximide (2.5 g/mL). Cell lysates are subjected to Western blot analysis, and immunoblotted for cleaved caspase-3, p53, p21, and HSP90 (loading control). CDDP: cisplatin

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cancer Res. 2018 Oct 1;78(19):5694-5705.  [Abstract]

    WT and S47 E1A/RAS cells are treated with 10 M Cisplatin (CDDP) for 24 hours. Cells are then fractionated into three fractions: whole cell lysate (W), mitochondria (M), and cytosol (C).

    Cisplatin purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 Feb;15(2):2583-2589.  [Abstract]

    MLN4924 increases CDDP induced apoptosis of esophageal cancer cells. EC1 and Kyse450 cells are treated with 1.6 μg/mL CDDP alone or in combina¬tion with 0.3 μM MLN for 72 h. Cleaved PARP are detected by western blotting.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2018 May;15(5):6469-6474.  [Abstract]

    MDA-MB-231 cells are grown and treated with CC-5013 (Len), Cisplatin (Cis), or their combination for 72 h and then subjected to western blot analysis.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Neurosci Lett. 2018 Aug 24:682:112-117.  [Abstract]

    After treatment of CDDP with or without the autophagy inhibitor CQ, the expression of LC3-II in the CQ+CDDP group is less than that in the CQ group but is higher than that in the CDDP group at 24 h and 96 h.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Cell Signal. 2017 Aug:36:108-116.  [Abstract]

    PAQR3 affects DNA damage repair. AGS cells are treated with different doses of VP-16 (for 24 h), Cisplatin (for 24 h) and NSC 123127 (for 10 h) as indicated, followed by immunoblotting with the antibodies.

    Cisplatin purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Apr 25;8(17):29125-29137.  [Abstract]

    Knockdown of ROC1 significantly enhances CDDP-induced apoptosis. TE1 and Kyse450 cells are transfected with siROC1 for 48 h and then treated with 1 μg/mL CDDP for 48 h. Knockdown efficiency and cleaved PARP are assessed by western blotting analysis. Protein expression is quantified and statically analyzed.

    Lipoxygenase アイソフォーム固有の製品をすべて表示:

    すべてのアイソフォームを表示
    5-LOX 12-LOX 15-LOX

    • 生物活性

    • プロトコル

    • 純度とドキュメンテーション

    • 参考文献

    • カスタマーレビュー

    製品説明

    Cisplatin (CDDP) is an antineoplastic chemotherapy agent by cross-linking with DNA and causing DNA damage in cancer cells. Cisplatin activates ferroptosis and induces autophagy[1][2][3].

    IC50 & Target

    DNA Alkylator/Crosslinker[1]
    体外実験

    Cisplatin (CDDP) causes apoptosis of HeLa cells in a dose-dependent manner, with a concentration of 30 μM Cisplatin resulting in death of greater than 90% of the cell population by 24 h of treatment. The kinetics of Cisplatin-induced apoptosis are examined using a 30 μM concentration. Cisplatin Activates the MEK/ERK Signaling Pathway, 20 and 30 μM Cisplatin, both of which results in significant apoptosis, leads to strong activation of ERK[1].
    Cisplatin (50 μM) produces time-dependent apoptosis in renal proximal tubular cell (RPTCs), causing cell shrinkage, a 50-fold increase in caspase 3 activity, a 4-fold increase in phosphatidylserine externalization, and 5- and 15-fold increases in chromatin condensation and DNA hypoploidy, respectively[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    シスプラチン 関連抗体
    体内実験

    In melanoma-bearing mice, Cisplatin (CDDP; 4 mg/kg B.W.) reduces the size and weight of the solid tumors, and HemoHIM supplementation with Cisplatin enhances the decrease of both the tumor size and weight[3].
    Cisplatin administration results in significant increases in the kidney weight as a percentage of the total body weight, urine volume, serum creatinine, and blood urea nitrogen by about 132, 315, 797, and 556% in comparison with the control rats, respectively[4].

    Note:
    Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

    Cisplatin can be used to induce acute kidney injury models[7][8].

    Induction of Acute Kidney Injury (AKI)[7][8]
    Background
    The pathogenesis of Cisplatin-induced acute kidney injury (AKI) is complex and Oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis are all participating in the progression of Cisplatin-induced AKI.Oxidative stress is a predominant mechanism of injury in cisplatin-induced AKI.
    Specific Modeling Methods
    Mice: C57BL/6 • male • 6-week-old (period: 2 weeks)
    Administration: 5 mg/kg • ip • once daily for 2 weeks
    Note
    (1) Suggest using male mice as female mice are more resistant to renal injury.
    (2) Mice can be deprived of food and water for 18 h prior to induction, and food and water are returned after administration.
    (3) Cisplatin can be dissolved in sterile saline solution to prepare injection working solution while protecting from light.
    Modeling Indicators
    Molecular changes: Increased indicators: Serum creatinine (SCr) levels, blood urea nitrogen (BUN) levels, neutrophil gelatinase-associated lipocalin (NGAL), 3-nitrotyrosine.
    Correlated Product(s): 84-B10 (HY-44307)

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
    臨床実験
    分子量

    300.05

    分子式

    Pt(NH3)2Cl2
    CAS 番号
    Appearance

    Solid

    Color

    Light yellow to yellow

    SMILES

    Cl[Pt](Cl)([NH3])[NH3]
    輸送条件

    Room temperature in continental US; may vary elsewhere.
    保管条件

    4°C, protect from light

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
    溶剤 & 溶解度
    体外: 

    DMF : 10 mg/mL (33.33 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Cisplatin's activity)

    H2O : 1 mg/mL (3.33 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Cisplatin's activity)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.3328 mL 16.6639 mL 33.3278 mL
    5 mM 0.6666 mL 3.3328 mL 6.6656 mL
    10 mM 0.3333 mL 1.6664 mL 3.3328 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始）

    C1

    ×
    体積 （開始）

    V1

    =
    濃度 （終了）

    C2

    ×
    体積 （終了）

    V2

    体内:

    For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  PBS

      Solubility: 1 mg/mL (3.33 mM); Clear solution; Need ultrasonic

    • Protocol 2

      Add each solvent one by one:  Saline

      Solubility: 2 mg/mL (6.67 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Calculation results:
    Working solution concentration: mg/mL
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
    純度とドキュメンテーション

    純度: 99.84%

    COA (247 KB) RP-HPLC (258 KB) Elemental Analysis Report (105 KB)

    取扱説明書 (2659 KB)
    参考文献
    細胞実験
    [1]

    HeLa and A549 cells are maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 100 units of Penicillin, and 100 μg of Streptomycin/mL. They are cultured at 37°C in a humidified chamber containing 5% CO2. For the induction of apoptosis, cells are plated in 60-mm dishes 1 day prior to Cisplatin (0-30 μM) treatment[1].

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
    動物実験
    [3][4]

    Mice[3]
    Mice are divided randomly into three groups (Control, Cisplatin and Cisplatin+HemoHIM), and each group consists of twenty mice. B16F0 melanoma (5×105 cells/mouse) is inoculated into subcutaneous femoral left region of mice at 3 days before an initial injection of Cisplatin. Cisplatin is injected intraperitoneally at 4 mg/kg body weight (B.W.) on day 0, 7 and 14 (total three injections). Experimental group is intubated with HemoHIM at a final concentration of 100 mg/kgB.W. by everyday from day -1 to day 16, while the control group received only water. On day 17 after initial injection of Cisplatin, all mice of each group are experimented, respectively, to evaluate tumor weight or tumor size. The tumor size is calculated as follows: tumor size=ab2/2, where a and b are the larger and smaller diameters, respectively.
    Rats[4]
    Male Sprague-Dawley rats weighing 200 to 250 g are divided at random into 4 groups of 4 or 5 animals each. The first group (control) received a vehicle (5% carboxymethyl cellulose sodium solution (CMC-Na), 5 mL/kg body wt., p.o.) used for Capsaicin (Cap). The second group received Cap (10 mg/kg/d, p.o.) in 5% CMC-Na (5 mL/kg), and the third received 5% CMC-Na for 6 consecutive days injected with Cisplatin (5 mg/kg in physiological saline solution, i.p.). The fourth group received Cap (10 mg/kg/d, p.o.) in 5% CMC-Na for 6 consecutive days after Cisplatin injection (5 mg/kg, i.p.). For all groups, Cap or vehicle is given twice daily. The selected Cap concentration and the dose administration schedule without inducing any rat intestinal damage are chosen using data from our preliminary experiments.

    MedChemExpress (MCE) はこれらの方法の精度を確認していません。 こちらは参照専用です。
    参考文献

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    H2O / DMF 1 mM 3.3328 mL 16.6639 mL 33.3278 mL 83.3195 mL
    DMF 5 mM 0.6666 mL 3.3328 mL 6.6656 mL 16.6639 mL
    10 mM 0.3333 mL 1.6664 mL 3.3328 mL 8.3319 mL
    15 mM 0.2222 mL 1.1109 mL 2.2219 mL 5.5546 mL
    20 mM 0.1666 mL 0.8332 mL 1.6664 mL 4.1660 mL
    25 mM 0.1333 mL 0.6666 mL 1.3331 mL 3.3328 mL
    30 mM 0.1111 mL 0.5555 mL 1.1109 mL 2.7773 mL

    * Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    Cisplatin Related Classifications

    • Molarity Calculator

    • Dilution Calculator

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    質量   濃度   体積   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    一般には略語で表示されます：C1V1 = C2V2

    濃度 （開始） × 体積 （開始） = 濃度 （終了） × 体積 （終了）
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    Cisplatin15663-27-1cis-Platinum CDDP cis-DiaminodichloroplatinumDNA Alkylator/CrosslinkerFerroptosisAutophagyPyroptosisLipoxygenaseLOXantineoplasticchemotherapydrugcross-linkingDNAdamageInhibitorinhibitorinhibit

    最近チェックした製品:

    オンラインお問い合わせ

    Your information is safe with us. * Required Fields.

    製品名

    		  

    カスタマ需要量 *

    お名前 *

    		 

    タイトル

    メールアドレス *

    		 

    電話番号 *

    デパートメント

    		 

    組纖名 *

    市区町村

    都道府県

    国或いは地域 *

    		      

    必ず会社名を記載ください。個人への返信は行いません。

    備考

    バルクお問い合わせ

    Inquiry Information

    製品名:
    Cisplatin
    製品番号:
    HY-17394
    数量:
    MCE 日本正規代理店:

    カスタマーレビュー

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    製品名

    		  

    Lot #

    お名前 *

    		 

    メールアドレス *

    電話番号 *

    		 

    部門 *

    組纖名 *

    		 

    国或いは地域 *

    備考

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.